Department for International Trade
Leading the UK delegation
- Hannah Williams hannah.williams@trade.gov.uk – Biopharma Lead
- Steve Kerr steve.kerr@trade.gov.uk – Scotland Office
- Louise Stock louise.stock@trade.gov.uk – Midlands England
- New England – Matt Clark matthew.clark@mobile.trade.gov.uk
- Mid-Atlantic and South East – Aubrey Powers aubrey.powers@mobile.trade.gov.uk
- Southern US – Autumn Waska autumn.waska@mobile.trade.gov.uk
- Southern California and South West – Bryanna Kolpak bryanna.kolpak@mobile.trade.gov.uk
Hannah Williams
Biopharma Lead
Department for International Trade - Midlands region
Leading the Midlands delegation
The Department for International Trade (DIT) helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade.
Louise Stock
Healthcare & Life Science Sector Specialist
Invest Northern Ireland
Leading the Northern Ireland delegation
Philip McCann
Michael Conlon
Brendan Mcguigan
Scottish Development International
Leading the Scotland delegation
Carcinotech, Causeway Therapeutics, DeepMatter, Elasmogen, Ingenza, Symbiosis, Pneumagen, TC Biopharm.
Jan Malek
Melina Hernandez
David Yeary
Almac Discovery
Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.
Alan Lamont
VP Business Development and licensing
Arctoris
Arctoris is a tech-enabled drug discovery company headquartered in Oxford and Boston. Arctoris combines its unique automation platform, Ulysses, with advanced computational approaches and a world-class team of seasoned drug hunters to guide and rapidly progress its wholly owned and partnered drug discovery programs in oncology and neurology.
Martin-Immanuel Bittner
Co-Founder and CEO
